Erratum: MicroRNA-122 ameliorates corneal allograft rejection through the downregulation of its target CPEB1 (Cell Death Discovery, (2017), 3, 1, (17021), 10.1038/cddiscovery.2017.21);MicroRNA-122 ameliorates corneal allograft rejection through the downregulation of its target CPEB1

Cell Death Discovery

Volumn 3, Issue 1, 2017, Pages

  Wang, Ting ^a   Li, Fengjie ^a   Geng, Wenwen ^a   Ruan, Qingguo ^b   Shi, Weiyun ^a  

^a SHANDONG EYE INSTITUTE   (China)

^b SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85038013100     PISSN: None     EISSN: 20587716     Source Type: Journal    
DOI: 10.1038/cddiscovery.2017.46     Document Type: Erratum

References (41)

1. Edelstein ML, Abedi MR, Wixon J, Edelstein RM. Gene therapy clinical trials worldwide 1989-2004-an overview. J Gene Med 2004; 6: 597–602.
2. Williams KA, Muehlberg SM, Lewis RF, Coster DJ. How successful is corneal transplantation? A report from the Australian corneal graft register. Eye 1995; 9: 219–227.
3. Boisjoly HM, Bernard PM, Dube I, Laughrea PA, Bazin R, Bernier J. Effect of factors unrelated to tissue matching on corneal transplant endothelial rejection. Am J Ophthalmol 1989; 107: 647–654.
4. Williams KA, Muehlberg SM, Wing SJ. The Australian Corneal Graft Registry. 1990 to 1992 report. Aust N Z J Ophthalmol 1993; 21: 1–48.
5. Des Marchais B, Bazin R, Boisjoly HM, Laughrea PA, Dube I, Lille S et al. Role of presensitization and donor-recipient crossmatching in corneal graft outcome. Cornea 1998; 17: 141–145.
6. Maumenee AE. Clinical aspects of the corneal homograft reaction. Invest Ophthalmol 1962; 1: 244–252.
7. Pleyer U, Legmann A, Mondino BJ, Lee DA. Use of collagen shields containing amphotericin B in the treatment of experimental Candida albicans-induced keratomycosis in rabbits. Am J Ophthalmol 1992; 113: 303–308.
8. Alldredge OC, Krachmer JH. Clinical types of corneal transplant rejection. Their manifestations, frequency, preoperative correlates, and treatment. Arch Ophthalmol 1981; 99: 599–604.
9. Vail A, Gore SM, Bradley BA, Easty DL, Rogers CA, Armitate WJ. Clinical and surgical factors influencing corneal graft survival, visual acuity, and astigmatism. Corneal transplant follow-up study collaborators. Ophthalmology 1996; 103: 41–49.
10. Beauregard C, Huq SO, Barabino S, Zhang Q, Kazlauskas A, Dana MR. Keratocyte apoptosis and failure of corneal allografts. Transplantation 2006; 81: 1577–1582.
11. Khan A, Nasr P, El-Charabaty E, El-Sayegh S. An insight into the immunologic events and risk assessment in renal transplantation. J Clin Med Res 2016; 8: 367–372.
12. Barcia RN, Dana MR, Kazlauskas A. Corneal graft rejection is accompanied by apoptosis of the endothelium and is prevented by gene therapy with bcl-xL. Am J Transplant 2007; 7: 2082–2089.
13. Oghumu S, Bracewell A, Nori U, Maclean KH, Balada-Lasat JM, Brodsky S et al. Acute pyelonephritis in renal allografts: a new role for microRNAs? Transplantation 2014; 97: 559–568.
14. Zununi S, Ardalan M. MicroRNA and renal allograft monitoring. Nephrourol Mon 2013; 5: 783–786.
15. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10: 111–122.
16. Lodish HF, Zhou B, Liu G, Chen CZ. Micromanagement of the immune system by microRNAs. Nat Rev Immunol 2008; 8: 120–130.
17. Klebe S, Coster DJ, Williams KA. Rejection and acceptance of corneal allografts. Curr Opin Organ Transplant 2009; 14: 4–9.
18. Di Giammartino DC, Nishida K, Manley JL. Mechanisms and consequences of alternative polyadenylation. Mol Cell 2011; 43: 853–866.
19. D'Ambrogio A, Nagaoka K, Richter JD. Translational control of cell growth and malignancy by the CPEBs. Cancer 2013; 13: 283–290.
20. Groppo R, Richter JD. CPEB control of NF-kappaB nuclear localization and interleukin-6 production mediates cellular senescence. Mol Cell Biol 2011; 31: 2707–2714.
21. Ru Y, Zhang Y, Zhao S. Expression and function of microRNAs in the cornea. Zhonghua Yan Ke Za Zhi 2015; 51: 229–235.
22. Shyu AB, Wilkinson MF, van Hoof A. Messenger RNA regulation: to translate or to degrade. EMBO J 2008; 27: 471–481.
23. Bae JS, Kim JH, Pasaje CF, Cheong HS, Lee TH, Koh IS et al. Association study of genetic variations in microRNAs with the risk of hepatitis B-related liver diseases. Dig Liver Dis 2012; 44: 849–854.
24. Moschos MM, Droutsas K, Sioziou A, Dettoraki M, Gazouli M. Mutational analysis of pre-miR-184 and hsa-mir-568 in Greek patients with sporadic keratoconus. Cornea 2016; 35: 631–633.
25. Zong R, Zhou T, Lin Z, Bao X, Xiu Y, Chen Y et al. Down-regulation of microRNA-184 is associated with corneal neovascularization. Invest Ophthalmol Vis Sci 2016; 57: 1398–1407.
26. Piedade D, Azevedo-Pereira JM. The role of microRNAs in the pathogenesis of herpesvirus infection. Viruses 2016; 8: E156.
27. Seo M, Choi JS, Rho CR, Joo CK, Lee SK. MicroRNA miR-466 inhibits lymphangiogenesis by targeting prospero-related homeobox 1 in the alkali burn corneal injury model. J Biomed Sci 2015; 22: 3.
28. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 2005; 309: 1577–1581.
29. Krutzfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 2005; 438: 685–689.
30. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006; 3: 87–98.
31. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006; 99: 671–678.
32. Yu Z, Raabe T, Hecht NB. MicroRNA Mirn122a reduces expression of the posttranscriptionally regulated germ cell transition protein 2 (Tnp2) messenger RNA (mRNA) by mRNA cleavage. Biol Reprod 2005; 73: 427–433.
33. Barnard DC, Ryan K, Manley JL, Richter JD. Symplekin and xGLD-2 are required for CPEB-mediated cytoplasmic polyadenylation. Cell 2004; 119: 641–651.
34. Kim JH, Richter JD. Opposing polymerase-deadenylase activities regulate cytoplasmic polyadenylation. Mol Cell 2006; 24: 173–183.
35. Burns DM, Richter JD. CPEB regulation of human cellular senescence, energy metabolism, and p53 mRNA translation. Genes Dev 2008; 22: 3449–3460.
36. Bava FA, Eliscovich C, Ferreira PG, Minana B, Ben-Dov C, Guigo R et al. CPEB1 coordinates alternative 3'-UTR formation with translational regulation. Nature 2013; 495: 121–125.
37. Niederkorn JY. Immune mechanisms of corneal allograft rejection. Curr Eye Res 2007; 32: 1005–1016.
38. Niederkorn JY. Immunology and immunomodulation of corneal transplantation. Int Rev Immunol 2002; 21: 173–196.
39. Lasseck J, Auw-Haedrich C, Boehringer D, Reinhard T. Keratocyte apoptosis increases in human corneal allografts during immune-mediated graft rejection. Br J Ophthalmol 2008; 92: 1429–1430.
40. Wang Z, Fayngerts S, Wang P, Sun H, Johnson DS, Ruan Q et al. TIPE2 protein serves as a negative regulator of phagocytosis and oxidative burst during infection. Proc Natl Acad Sci USA 2012; 109: 15413–15418.
41. Sun H, Zhuang G, Chai L, Wang Z, Johnson D, Ma Y et al. TIPE2 controls innate immunity to RNA by targeting the phosphatidylinositol 3-kinase-Rac pathway. J Immunol 2012; 189: 2768–2773.